Ways to disseminate device safety information considered
This article was originally published in The Silver Sheet
FDA is scrutinizing ways to release device safety information to the public, seeking to be timely without sacrificing completeness and accuracy. "The historical strategy of waiting to communicate until the end of a lengthy evaluation and negotiation process doesn't work," says Nancy Ostrove, senior advisor for risk communication in FDA's Office of Planning. Patients and doctors want information earlier than ever before, she says, yet risk assessment remains a lengthy and complex process. Consequently, FDA and manufacturers walk a "parallel tightrope," making judgments based on less-than-complete data and deciding how and when to communicate that data to the public. FDA has never systematically analyzed how the public receives and interprets safety information. That task will be the primary mission of the new 15-member Risk Communication Advisory Committee, set to convene for the first time early this year ("The Silver Sheet" November 2007)
You may also be interested in...
A randomized COVID-19 study spanning the whole of the UK could help to bolster the UK’s reputation as a location for future clinical trials. It is also being seen partly as the result of the UK regulator's "decisive action" in fast-tracking trials for potential COVID-19 therapies.
Manufacturers of endoscopic equipment, biofeedback devices and thermometers were among those cited for regulatory violations in US FDA warning letters this week. A total of four device-related enforcement missives were released by the agency.
The biopharma industry has struggled to recruit patients into clinical trials that adequately reflect the diverse patient populations they hope to reach with new products. Failure to improve minority subgroup participation now will cost trial sponsors later.